Smoldering Multiple Myeloma Can Be Slowed by Lenalidomide
Early treatment with lenalidomide can stave off multiple myeloma and provide longer progression-free survival (PFS) than just monitoring alone.
Related Articles
Pelareorep Combination Shows Manageable Safety in Metastatic Pancreatic Cancer
Cohort 5 of the ongoing phase 1/2 GOBLET study evaluated the safety of pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in patients…
Expert Insights: Evolving Treatment Landscape in NDMM
Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma (NDMM) has evolved from conventional chemotherapy to modern regimens incorporating novel agents like proteasome…
NALIRIFOX Numerically Improves OS Vs FOLFIRINOX in Metastatic PDAC
A 3-cohort retrospective analysis compared patients who met eligibility for the NAPOLI 3 trial with all-comers treated with FOLFIRINOX for PDAC.
Patients With Extrapancreatic NETs Experience Improved PFS from Cabozantinib
Patients who received cabozantinib experienced a PFS of 8.5 months vs 5.6 months with placebo, a subgroup analysis from the CABINET trial found.
Pamrevlumab Combo Does Not Improve Survival in Advanced Pancreatic Cancer
Results from the phase 3 LAPIS trial showed pamrevlumab/chemotherapy did not improve survival vs placebo/chemotherapy in locally advanced, unresectable pancreatic cancer.
Later-Line Surufatinib Combo Shows Promising Activity in Metastatic PDAC
Updated phase 2 results support further investigation of surufatinib plus TAS-012 in a larger cohort of patients with pancreatic ductal adenocarcinoma.
Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma
Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the…
TACE Plus Camrelizumab/Rivoceranib Extends PFS in Unresectable Liver Cancer
Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.
ZL-1310 Receives Orphan Drug Designation in Small Cell Lung Cancer
A phase 1a/1b trial showed that ZL-1310 elicited an ORR of 74%, all of which were PRs, in patients with SCLC who received prior chemotherapy.
Fulvestrant Yields No OS Differences Vs Anastrozole in HR+ Breast Cancer
Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.